Belpointe Asset Management »

Candel Therapeutics shares owned by Belpointe Asset Management

Quarter-by-quarter ownership of Candel Therapeutics (CADL) shares owned by Belpointe Asset Management from 13F filings

Historical chart of Belpointe Asset Management investment in Candel Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Candel Therapeutics held by Belpointe Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Candel Therapeutics by Belpointe Asset Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $224k 46k 4.90

More positions owned by Belpointe Asset Management

Spdr S&p 500 Etf Etf (SPY)
Invesco QQQ Trust Etf (QQQ)
Apple (AAPL)
NVIDIA Corporation (NVDA)
Collaborative Investmnt Ser Etf (PLGI)
Anydrus Advantage Etf Etf (NDOW)
Schwab U.S. Large-Cap Growth ETF Etf (SCHG)
Nelson Select Etf (NELS)
Amazon (AMZN)
Microsoft Corporation (MSFT)
Rareview Total Return Bond Etf Etf (RTRE)
Schwab Strategic Tr Etf (SCHX)
Vanguard S&P 500 ETF Etf (VOO)
Sch Fnd Us Lg Etf schwb fdt us lg (FNDX)
Ishares Tr Etf (IVV)

View all positions for Belpointe Asset Management

Top funds holding Candel Therapeutics

FMR
BlackRock
Portolan Capital Management
Acorn Capital Advisors
Vanguard Capital Management
Vanguard Group
Vestal Point Capital
Millennium Management
Geode Capital Management
Halter Ferguson Financial
State Street Corporation
Sands Capital Ventures
Northern Trust
Vanguard Fiduciary Trust
Vanguard Portfolio Management

View all funds holding Candel Therapeutics